

Colin R Lindsay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1517519/publications.pdf>

Version: 2024-02-01

34
papers

1,335
citations

430874

18
h-index

345221

36
g-index

37
all docs

37
docs citations

37
times ranked

2485
citing authors

#	ARTICLE	IF	CITATIONS
1	P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. <i>Nature Communications</i> , 2011, 2, 555.	12.8	152
2	KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition. <i>EBioMedicine</i> , 2019, 41, 711-716.	6.1	142
3	High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 1408-1415.	1.2	105
4	Rac1 Drives Melanoblast Organization during Mouse Development by Orchestrating Pseudopod-Driven Motility and Cell-Cycle Progression. <i>Developmental Cell</i> , 2011, 21, 722-734.	7.0	98
5	A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 701-711.	7.0	86
6	A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups. <i>Annals of Oncology</i> , 2017, 28, 1523-1531.	1.2	80
7	Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer. <i>BMC Cancer</i> , 2016, 16, 168.	2.6	69
8	EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2019, 117, 60-68.	2.8	68
9	Circulating Tumor Cells with Aberrant <i>ALK</i> Copy Number Predict Progression-Free Survival during Crizotinib Treatment in <i>ALK</i> -Rearranged Non-Small Cell Lung Cancer Patients. <i>Cancer Research</i> , 2017, 77, 2222-2230.	0.9	64
10	Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network. <i>Lung Cancer</i> , 2016, 97, 99-104.	2.0	56
11	Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial. <i>Annals of Oncology</i> , 2019, 30, 1114-1120.	1.2	54
12	KRAS: Reasons for optimism in lung cancer. <i>European Journal of Cancer</i> , 2018, 99, 20-27.	2.8	43
13	Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. <i>Future Oncology</i> , 2009, 5, 421-432.	2.4	38
14	Direct Ras G12C inhibitors: crossing the rubicon. <i>British Journal of Cancer</i> , 2019, 121, 197-198.	6.4	37
15	Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts. <i>Annals of Oncology</i> , 2020, 31, 873-883.	1.2	35
16	Method for semi-automated microscopy of filtration-enriched circulating tumor cells. <i>BMC Cancer</i> , 2016, 16, 477.	2.6	29
17	The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1605-1629.	3.1	25
18	On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma. <i>Lung Cancer</i> , 2021, 160, 152-165.	2.0	24

#	ARTICLE	IF	CITATIONS
19	SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting. <i>British Journal of Cancer</i> , 2017, 117, 938-946.	6.4	18
20	Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 589-595.	4.2	17
21	CD52, CD22, CD26, EG5 and IGF-1R expression in thymic malignancies. <i>Lung Cancer</i> , 2017, 108, 168-172.	2.0	14
22	A Rac1-Independent Role for P-Rex1 in Melanoblasts. <i>Journal of Investigative Dermatology</i> , 2015, 135, 314-318.	0.7	10
23	Loss of autophagy affects melanoma development in a manner dependent on PTEN status. <i>Cell Death and Differentiation</i> , 2021, 28, 1437-1439.	11.2	10
24	Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 107-121.	3.2	8
25	EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 1653-1665.	2.8	8
26	XELOX in colorectal cancer: a convenient option for the future?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2011, 5, 9-19.	3.0	7
27	Lessons for molecular diagnostics in oncology from the Cancer Research UK Stratified Medicine Programme. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 287-289.	3.1	7
28	The insulin-like growth factor system and its receptors: A potential novel anticancer target. <i>Biologics: Targets and Therapy</i> , 2008, 2, 855.	3.2	6
29	Effectiveness of dabrafenib in the treatment of patients with BRAF V600A mutated metastatic melanoma in a Named Patient Program. <i>Melanoma Research</i> , 2019, 29, 527-532.	1.2	6
30	Recombinant human epoetin beta in the treatment of chemotherapy-related anemia. <i>Therapeutics and Clinical Risk Management</i> , 2009, 5, 261.	2.0	5
31	Thymic malignancies: Moving forward with new systemic treatments. <i>Cancer Treatment Reviews</i> , 2016, 46, 27-34.	7.7	4
32	Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. <i>ESMO Open</i> , 2018, 3, e000408.	4.5	4
33	How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?. <i>Future Oncology</i> , 2013, 9, 825-829.	2.4	2
34	A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, e44-e45.	1.1	1